Imiquimod Cream
NDC Package 68682-272-75
Package Information
Imiquimod cream is a medication used to treat certain types of growths on the skin. This formulation utilizes a cream delivery system. Marketed by Oceanside Pharmacueticals, this product is identified by NDC 68682-272 and is authorized under FDA application NDA022483.
Identification & Billing
- RxCUI: 967017 - imiquimod 3.75 % Topical Cream
- RxCUI: 967017 - imiquimod 37.5 MG/ML Topical Cream
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68682 - Oceanside Pharmacueticals
- 68682-272 - Imiquimod
- 68682-272-75 - 1 BOTTLE, PUMP in 1 CARTON / 7.5 g in 1 BOTTLE, PUMP
- 68682-272 - Imiquimod
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68682-272-75 identifies a specific commercial package of 1 bottle, pump in 1 carton / 7.5 g in 1 bottle, pump of Imiquimod, a human prescription drug labeled by Oceanside Pharmacueticals. This cream is formulated for topical use and contains imiquimod as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oceanside Pharmacueticals on June 27, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of growths on the skin. These are precancerous growths (actinic keratoses), a certain type of skin cancer (superficial basal cell carcinoma), and warts on the outside of the genitals/anus. Treating these conditions can decrease complications from them. Imiquimod belongs to a group of drugs called immune response modifiers. It is believed to work by helping to activate your immune system to fight these abnormal skin growths. This product is not recommended for use on children under 12 years of age unless specifically directed by your doctor.
How is this Oceanside Pharmacueticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68682027275. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 7.5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.